Cargando…

Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases

BACKGROUND: An advance in the treatment of schizophrenia is the development of long-acting intramuscular formulations of antipsychotics, such as olanzapine long-acting injection (LAI). During clinical trials, a post-injection syndrome characterized by signs of delirium and/or excessive sedation was...

Descripción completa

Detalles Bibliográficos
Autores principales:	Detke, Holland C, McDonnell, David P, Brunner, Elizabeth, Zhao, Fangyi, Sorsaburu, Sebastian, Stefaniak, Victoria J, Corya, Sara A
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2010
Materias:	Research article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2895589/ https://www.ncbi.nlm.nih.gov/pubmed/20537128 http://dx.doi.org/10.1186/1471-244X-10-43

Ejemplares similares

Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism
por: McDonnell, David P, et al.
Publicado: (2010)

Olanzapine long-acting injection: a review of first experiences of post-injection delirium/sedation syndrome in routine clinical practice
por: Bushe, Chris J, et al.
Publicado: (2015)

A pooled analysis of injection site-related adverse events in patients with schizophrenia treated with olanzapine long-acting injection
por: Atkins, Susan, et al.
Publicado: (2014)

Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injection
por: Ascher-Svanum, Haya, et al.
Publicado: (2014)

Efficacy of olanzapine long-acting injection in patients with acutely exacerbated schizophrenia: an insight from effect size comparison with historical oral data
por: Detke, Holland C, et al.
Publicado: (2012)

Long-term safety and efficacy of olanzapine long-acting injection in patients with schizophrenia or schizoaffective disorder: a 6-year, multinational, single-arm, open-label study
por: McDonnell, David P., et al.
Publicado: (2014)

Within‐drug benefit‐risk evaluation of olanzapine long‐acting injection at one and two years of treatment
por: Detke, Holland C., et al.
Publicado: (2014)

Early response predicts subsequent response to olanzapine long-acting injection in a randomized, double-blind clinical trial of treatment for schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2011)

Pharmacokinetics of olanzapine long-acting injection: the clinical perspective
por: Heres, Stephan, et al.
Publicado: (2014)

Case series profile of olanzapine post‐injection delirium/sedation syndrome
por: Seebaluck, Jason, et al.
Publicado: (2022)

Postinjection Delirium/Sedation Syndrome with Olanzapine Depot Injection
por: Sarangula, Sadhvi Mythili, et al.
Publicado: (2016)

Predictors of psychiatric hospitalization during 6 months of maintenance treatment with olanzapine long-acting injection: post hoc analysis of a randomized, double-blind study
por: Ascher-Svanum, Haya, et al.
Publicado: (2013)

Baseline characteristics and hospitalizations in patients with schizophrenia receiving olanzapine long-acting injection: an interim analysis from a non-interventional, prospective observational safety study
por: Jones, Meghan E., et al.
Publicado: (2015)

Postinjection delirium/sedation syndrome in patients with schizophrenia receiving olanzapine long-acting injection: results from a large observational study
por: Meyers, Kristin J., et al.
Publicado: (2017)

Clinical outcomes with olanzapine long-acting injection: impact of the 3-hour observation period on patient satisfaction and well-being
por: Anand, Ernie, et al.
Publicado: (2016)

Treatment-completion rates with olanzapine long-acting injection versus risperidone long-acting injection in a 12-month, open-label treatment of schizophrenia: indirect, exploratory comparisons
por: Ascher-Svanum, Haya, et al.
Publicado: (2012)

A 6-year open-label study of the efficacy and safety of olanzapine long-acting injection in patients with schizophrenia: a post hoc analysis based on the European label recommendation
por: Anand, Ernie, et al.
Publicado: (2015)

Patient and Health Care Provider Perspectives on Long Acting Injectable Antipsychotics in Schizophrenia and the Introduction of Olanzapine Long-Acting Injection
por: Wehring, Heidi J., et al.
Publicado: (2011)

Dose-associated changes in safety and efficacy parameters observed in a 24-week maintenance trial of olanzapine long-acting injection in patients with schizophrenia
por: Hill, Angela L, et al.
Publicado: (2011)

Profile of olanzapine long-acting injection for the maintenance treatment of adult patients with schizophrenia
por: Di Lorenzo, Rosaria, et al.
Publicado: (2010)

Postinjection delirium/sedation syndrome with long-acting olanzapine pamoate in a middle-aged female
por: Upadhyay, Apoorva, et al.
Publicado: (2017)

Patient perspectives in the development and use of long-acting antipsychotics in schizophrenia: focus on olanzapine long-acting injection
por: Citrome, Leslie
Publicado: (2009)

Long-acting injectable antipsychotics: focus on olanzapine pamoate
por: Lindenmayer, JP
Publicado: (2010)

A study on blood pressure changes following Olanzapine Long Acting Injection (LAI) in schizophrenia
por: Gakkhar, Shivam, et al.
Publicado: (2022)

Are the Long-Acting Intramuscular Formulations of Risperidone or Paliperidone Palmitate Associated with Post-Injection Delirium/Sedation Syndrome? An Assessment of Safety Databases
por: Alphs, Larry, et al.
Publicado: (2011)

Switching to olanzapine long-acting injection from either oral olanzapine or any other antipsychotic: comparative post hoc analyses
por: Ciudad, Antonio, et al.
Publicado: (2013)

Evaluating adult forensic staff knowledge of olanzapine long-acting injection post injection syndrome: a service improvement project
por: Clark, Annalie, et al.
Publicado: (2021)

Post-Injection Delirium/Sedation Syndrome: A Case Report and 2-Year Follow-Up
por: Podgorná, Gabriela, et al.
Publicado: (2022)

Schizophrenia symptoms and functioning in patients receiving long-term treatment with olanzapine long-acting injection formulation: a pooled analysis
por: Peuskens, Joseph, et al.
Publicado: (2012)

A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future
por: Citrome, Leslie, et al.
Publicado: (2019)

The Use of Long-Acting Injectable Antipsychotics in Schizophrenia
por: Miyamoto, Seiya, et al.
Publicado: (2017)

Acceptance of the Deltoid Muscle Injection of Aripiprazole Long-acting Injectable in the Patients with Schizophrenia
por: Kamei, Hiroyuki, et al.
Publicado: (2020)

Effectiveness and safety of oral olanzapine treatment transitioned from rapid-acting intramuscular olanzapine for agitation associated with schizophrenia
por: Katagiri, Hideaki, et al.
Publicado: (2018)

Long-Acting Injectable Antipsychotics in First-Episode Schizophrenia
por: Parellada, Eduard, et al.
Publicado: (2012)

Long-acting Injectable Antipsychotics in First-episode Schizophrenia
por: Jeong, Hyun-Ghang, et al.
Publicado: (2013)

The place of long-acting injectable antipsychotics in the treatment of schizophrenia
por: Kane, John M., et al.
Publicado: (2023)

Comparison of efficacy of haloperidol and olanzapine in the treatment of delirium
por: Jain, Rajan, et al.
Publicado: (2017)

Quality of life in children and adolescents with bipolar I depression treated with olanzapine/fluoxetine combination
por: Walker, Daniel J., et al.
Publicado: (2017)

Acute Metabolic Effects of Olanzapine Depend on Dose and Injection Site
por: Klingerman, Candice M., et al.
Publicado: (2015)

Use of Aripiprazole Long Acting Injection in Negative Symptoms of Schizophrenia
por: James, Suneeta, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_dor9rebi3jr2tt4mvj7nun0fjm